Clinical, neuropsychologic, and molecular data from 17 patients
Mean or % | SD | No. of Patients | |
---|---|---|---|
Age at MR imaging | 68 years | 5.5 | 17 |
Age at tremor onset | 58.3 years | 3.9 | 15 |
Age at ataxia onset | 61.6 years | 5.6 | 15 |
Significant impairment | |||
Writing | 89% | 17 | |
Walking | 50% | 17 | |
Tremor | 89% | 17 | |
Character of tremor | |||
Kinetic > postural | 100% | 15 | |
Discrete resting tremor | 58% | 15 | |
Gait ataxia | 89% | 17 | |
Dyssynergia | 72% | 17 | |
Tone, mild increase | 47% | 14 | |
Neuropsychologic data | |||
VIQ | 98 | 16 | 6 |
PIQ | 83 | 17 | 6 |
FSIQ | 91 | 18 | 6 |
Executive function deficits | 100% | 6 | |
VIQ < 85 | 33% | 6 | |
PIQ < 85 | 66% | 6 | |
Impotence | 100% | 6 | |
CGG repeat | 86 | 10 | 17 |
FMRP level | 77.5%* | 9% | 6 |
mRNA level | 2.53-fold† | 0.48 | 6 |
* Percentage of lymphocytes that are positive for fragile X mental retardation 1 protein immuno-cytochemical staining for fragile X mental retardation 1 protein (19,46).
† 2.53-fold increase over normal (16,46).
Note.—VIQ indicates verbal intelligence quotient; PIQ, performance intelligence level; FSIQ, full scale intelligence quotient; FMRP, fragile X mental retardation 1 protein; mRNA, messenger RNA.